Rejuvenation Technologies Inc.
ActivemRNA therapeutics to extend healthspan entering clinical trials
What it does
Stanford-patented essential drug platform unlocks the healthspan, which is limited by short telomeres. Extends mouse lifespan by equivalent of 10 years in humans. Reverses 5-10 years of telomere shortening with one dose in one day. Preclinical efficacy in 4 organ systems including immune system. Entering clinical stage. CEO is Subject #1 in longevity trial. 50+ granted patents, 7 patent families. FDA INTERACT cleared. Raising $10M seed extension ($2M+ wired) to fund 3 investigator-initiated trials. Readouts in Q3 2027. $6.8B in comparable mRNA-LNP M&A in last 12 months.
Next to it in Healthcare and bio · mRNA therapeutics for longevity
- Helix NanotechnologiesY Combinator W17
Next-generation mRNA platform to solve cancer, COVID and climate.
- CircumventY Combinator S18
Utilizing monogenic disorders to inform and solve highly complex…
- Turn BiotechnologiesPlug and Play
Turn.bio is a biotechnology company developing drugs to reverse aging and age-related diseases. Utilizing a patented mRNA platform technology, ERA, the company is combating the effects of aging on the epigenome. The company’s proprietary mRNA platform technology, ERA and eTurna, a delivery platf...
- Gilgamesh PharmaceuticalsY Combinator S20
Gilgamesh Pharmaceuticals, a Clinical stage biotechnology company…
- Kernal BiologicsY Combinator S20
Kernal is creating mRNA 2.0 therapies that work in specific cells
- Cell Reserves IncSOSV SOSV IndieBio RebelBio 03
Developing novel protein and peptide-based therapeutics for the treatment of diseases
- Laguna BioSOSV SOSV IndieBio SF 13
Next generation bispecific antibody cancer therapy.
- Entelexo BiotherapeuticsY Combinator W21
Creating a New Class of Drugs to Address Incurable Autoimmune Diseases